NASDAQ:CALT Calliditas Therapeutics AB (publ) - CALT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. $22.40 -0.72 (-3.11%) (As of 03/28/2023 03:59 PM ET) Add Compare Share Share Today's Range$21.92▼$23.0050-Day Range$16.80▼$25.2452-Week Range$10.82▼$25.49Volume13,687 shsAverage Volume14,859 shsMarket Capitalization$667.30 millionP/E RatioN/ADividend YieldN/APrice Target$79.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Calliditas Therapeutics AB (publ) MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside249.9% Upside$79.00 Price TargetShort InterestHealthy0.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.47) to $4.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector688th out of 1,002 stocksPharmaceutical Preparations Industry338th out of 488 stocks 3.4 Analyst's Opinion Consensus RatingCalliditas Therapeutics AB (publ) has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.00, Calliditas Therapeutics AB (publ) has a forecasted upside of 249.9% from its current price of $22.58.Amount of Analyst CoverageCalliditas Therapeutics AB (publ) has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.08% of the outstanding shares of Calliditas Therapeutics AB (publ) have been sold short.Short Interest Ratio / Days to CoverCalliditas Therapeutics AB (publ) has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calliditas Therapeutics AB (publ) has recently increased by 58.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalliditas Therapeutics AB (publ) does not currently pay a dividend.Dividend GrowthCalliditas Therapeutics AB (publ) does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CALT. Previous Next 3.0 News and Social Media Coverage News SentimentCalliditas Therapeutics AB (publ) has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Calliditas Therapeutics AB (publ) this week, compared to 1 article on an average week.Search Interest4 people have searched for CALT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Calliditas Therapeutics AB (publ) to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Calliditas Therapeutics AB (publ) is held by insiders.Percentage Held by InstitutionsOnly 3.13% of the stock of Calliditas Therapeutics AB (publ) is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Calliditas Therapeutics AB (publ) are expected to grow in the coming year, from ($0.47) to $4.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Calliditas Therapeutics AB (publ) is -13.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calliditas Therapeutics AB (publ) is -13.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalliditas Therapeutics AB (publ) has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Calliditas Therapeutics AB (publ) (NASDAQ:CALT) StockCalliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.Read More Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address CALT Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $24.10March 22, 2023 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading VolumeMarch 28, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …March 19, 2023 | finance.yahoo.com3 Supercharged Stocks Near 52-Week Highs That Could Keep ClimbingMarch 16, 2023 | barrons.comCalliditas Therapeutics AB ADRMarch 13, 2023 | msn.comCalliditas jumps 35% on prospects for full approval of kidney disease therapyMarch 3, 2023 | benzinga.comCalliditas Therapeutics Stock (NASDAQ:CALT), Guidance and ForecastMarch 1, 2023 | finance.yahoo.comAnalyst Sits On Fence While Initiating Calliditas Citing 'Near-Term Opportunity But Longer-Term Questions'March 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 1, 2023 | seekingalpha.comCalliditas: Underfollowed Swedish Biotech Focusing On Rare Kidney DiseaseFebruary 24, 2023 | msn.comCalliditas Therapeutics reports Q4 resultsFebruary 23, 2023 | finance.yahoo.comCalliditas - Year-End Report, 2022February 2, 2023 | benzinga.comFirst Alberta Clinical Site for Study of Psychedelic-Assisted Treatment for Alcohol Use Disorder ApprovedFebruary 2, 2023 | finance.yahoo.comCalliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyJanuary 25, 2023 | seekingalpha.comPliant Therapeutics begins $175M public offering; closes up 35%January 6, 2023 | seekingalpha.comChinook Therapeutics: Best Biotech For Kidney Disease Exposure, With CatalystsDecember 21, 2022 | finance.yahoo.comCalliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022December 13, 2022 | finance.yahoo.comCalliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in JapanNovember 15, 2022 | finanznachrichten.deCalliditas Therapeutics: Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPANovember 15, 2022 | finance.yahoo.comCalliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPANovember 14, 2022 | finance.yahoo.comCalliditas Therapeutics: Interim Report Q3, 2022November 7, 2022 | finanznachrichten.deCalliditas Therapeutics: Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment LandscapeOctober 21, 2022 | finance.yahoo.comCalliditas Therapeutics' nomination committee composition for the AGM 2023October 19, 2022 | finance.yahoo.comKidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA NephropathyOctober 6, 2022 | benzinga.comXTORTX Therapeutics shares are trading lower after the company announced a $5 million public offering.September 20, 2022 | finance.yahoo.comCalliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathyAugust 19, 2022 | seekingalpha.comCalliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64MSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address CALT Company Calendar Last Earnings11/17/2021Today3/28/2023Next Earnings (Estimated)5/17/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALT CUSIPN/A CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees66Year Founded2004Price Target and Rating Average Stock Price Forecast$79.00 High Stock Price Forecast$79.00 Low Stock Price Forecast$79.00 Forecasted Upside/Downside+249.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net Margins-56.10% Pretax Margin-50.99% Return on Equity-55.18% Return on Assets-27.29% Debt Debt-to-Equity Ratio0.95 Current Ratio4.34 Quick Ratio4.33 Sales & Book Value Annual Sales$79.63 million Price / Sales8.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.55 per share Price / Book8.85Miscellaneous Outstanding Shares29,790,000Free Float29,131,000Market Cap$672.66 million OptionableNot Optionable Beta1.48 Social Links Key ExecutivesMs. Renee Aguiar-Lucander (Age 60)Chief Exec. Officer Mr. Fredrik Johansson (Age 45)Chief Financial Officer Dr. Katayoun Welin-Berger Ph.D. (Age 54)VP of Operations Dr. Johan Haggblad Ph.D. (Age 64)Chief Scientific Officer Mr. Mikael Widell (Age 64)Head of Communications & IR Mr. Jonathan A. Schur (Age 69)Group Gen. Counsel Ms. Sandra FrithiofHead of HRMs. Ann-Kristin Myde BSc (Age 67)Head of Clinical Devel. & VP of Project Management Mr. Andrew B. Udell B.Sc. (Age 52)M.B.A., Pres of North America Commercial Dr. Krassimir Mitchev (Age 63)Head of Medical Affairs More ExecutivesKey CompetitorsIGM BiosciencesNASDAQ:IGMSPureTech HealthNASDAQ:PRTCANI PharmaceuticalsNASDAQ:ANIPIDEAYA BiosciencesNASDAQ:IDYAPOINT Biopharma GlobalNASDAQ:PNTView All CompetitorsInstitutional OwnershipOptiver Holding B.V.Sold 1,484 shares on 2/10/2023Ownership: 0.037%HBK Sorce Advisory LLCBought 45,000 shares on 2/9/2023Ownership: 0.302%Simplex Trading LLCBought 1,000 shares on 2/2/2023Ownership: 0.000%Ironwood Investment Management LLCSold 2,433 shares on 1/31/2023Ownership: 0.088%View All Institutional Transactions CALT Stock - Frequently Asked Questions Should I buy or sell Calliditas Therapeutics AB (publ) stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CALT shares. View CALT analyst ratings or view top-rated stocks. What is Calliditas Therapeutics AB (publ)'s stock price forecast for 2023? 4 brokerages have issued twelve-month price objectives for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price forecasts range from $79.00 to $79.00. On average, they expect the company's stock price to reach $79.00 in the next twelve months. This suggests a possible upside of 249.9% from the stock's current price. View analysts price targets for CALT or view top-rated stocks among Wall Street analysts. How have CALT shares performed in 2023? Calliditas Therapeutics AB (publ)'s stock was trading at $17.00 at the start of the year. Since then, CALT stock has increased by 32.8% and is now trading at $22.58. View the best growth stocks for 2023 here. Are investors shorting Calliditas Therapeutics AB (publ)? Calliditas Therapeutics AB (publ) saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 22,700 shares, an increase of 58.7% from the February 28th total of 14,300 shares. Based on an average trading volume of 14,300 shares, the short-interest ratio is presently 1.6 days. View Calliditas Therapeutics AB (publ)'s Short Interest. When is Calliditas Therapeutics AB (publ)'s next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 17th 2023. View our CALT earnings forecast. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Wednesday, November, 17th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.62. The company earned $22.92 million during the quarter. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 55.18% and a negative net margin of 56.10%. During the same period in the prior year, the business earned ($0.62) earnings per share. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX). When did Calliditas Therapeutics AB (publ) IPO? (CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager. What is Calliditas Therapeutics AB (publ)'s stock symbol? Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT." Who are Calliditas Therapeutics AB (publ)'s major shareholders? Calliditas Therapeutics AB (publ)'s stock is owned by many different retail and institutional investors. Top institutional investors include HBK Sorce Advisory LLC (0.30%), Ironwood Investment Management LLC (0.09%), Optiver Holding B.V. (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Calliditas Therapeutics AB (publ)'s stock price today? One share of CALT stock can currently be purchased for approximately $22.58. How much money does Calliditas Therapeutics AB (publ) make? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has a market capitalization of $672.66 million and generates $79.63 million in revenue each year. The company earns $-40,860,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. How can I contact Calliditas Therapeutics AB (publ)? Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The official website for the company is www.calliditas.se. The company can be reached via phone at 46-0-841-130-05 or via email at mikael.widell@calliditas.com. This page (NASDAQ:CALT) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.